[go: up one dir, main page]

DE69635864D1 - Rekombinante rna-replikase von hepatitis-c-virus - Google Patents

Rekombinante rna-replikase von hepatitis-c-virus

Info

Publication number
DE69635864D1
DE69635864D1 DE69635864T DE69635864T DE69635864D1 DE 69635864 D1 DE69635864 D1 DE 69635864D1 DE 69635864 T DE69635864 T DE 69635864T DE 69635864 T DE69635864 T DE 69635864T DE 69635864 D1 DE69635864 D1 DE 69635864D1
Authority
DE
Germany
Prior art keywords
hcv
rdrp
hepatitis
virus
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69635864T
Other languages
English (en)
Other versions
DE69635864T2 (de
Inventor
H Hagedorn
H Al
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of DE69635864D1 publication Critical patent/DE69635864D1/de
Application granted granted Critical
Publication of DE69635864T2 publication Critical patent/DE69635864T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69635864T 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus Expired - Fee Related DE69635864T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27
US4383P 1995-09-27
PCT/US1996/015571 WO1997012033A1 (en) 1995-09-27 1996-09-27 Recombinant hepatitis c virus rna replicase

Publications (2)

Publication Number Publication Date
DE69635864D1 true DE69635864D1 (de) 2006-04-27
DE69635864T2 DE69635864T2 (de) 2006-10-26

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635864T Expired - Fee Related DE69635864T2 (de) 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus

Country Status (8)

Country Link
US (2) US5981247A (de)
EP (1) EP0859833B1 (de)
JP (1) JP4191797B2 (de)
AT (1) ATE318896T1 (de)
AU (1) AU719122B2 (de)
CA (1) CA2233309A1 (de)
DE (1) DE69635864T2 (de)
WO (1) WO1997012033A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
CA2325016A1 (en) * 1998-04-02 1999-10-14 Viropharma Incorporated Hepatitis c virus ns5b compositions and methods of use thereof
US6639053B1 (en) 1998-06-24 2003-10-28 Tetsuya Toyoda HCV-derived RNA polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600451A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
EP1270737A4 (de) * 2000-04-07 2004-06-16 Shionogi & Co Testverfahren mit vorinkubationsschritt
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
CA2437072A1 (en) * 2001-01-31 2002-08-08 Bristol-Myers Squibb Pharma Company In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
EP1399541A4 (de) * 2001-05-22 2005-04-13 Univ Chicago Einzelstrang-dna-abhängige rna polymerase des virions n4
US20030170810A1 (en) * 2001-09-18 2003-09-11 Masoud Vedadi Methods and apparatuses for purification
US20030104445A1 (en) * 2001-09-25 2003-06-05 Hayes Robert J. RNA dependent RNA polymerase mediated protein evolution
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
AU2002360394A1 (en) * 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
PL2604620T5 (pl) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
US7329732B2 (en) * 2004-01-09 2008-02-12 Merck & Co., Inc. HCV RNA-dependent RNA polymerase
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
CN101142226A (zh) 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物
AR056327A1 (es) 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
EP2476690A1 (de) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Verbindungen und pharmazeutische Zusammensetzungen für die Behandlung von Virusinfektionen
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
CN102713630A (zh) 2009-11-14 2012-10-03 弗·哈夫曼-拉罗切有限公司 用于预测对hcv治疗的快速应答的生物标志物
AU2010326781A1 (en) 2009-12-02 2012-04-19 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to HCV treatment
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
MX2013000906A (es) 2010-07-22 2013-02-27 Novartis Ag Compuestos de tiofeno 2, 3, 5-trisustituidos y usos de los mismos.
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3038601B1 (de) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
WO1997012033A1 (en) 1997-04-03
EP0859833A4 (de) 2001-03-28
JP4191797B2 (ja) 2008-12-03
AU7200796A (en) 1997-04-17
CA2233309A1 (en) 1997-04-03
US6248589B1 (en) 2001-06-19
EP0859833A1 (de) 1998-08-26
DE69635864T2 (de) 2006-10-26
AU719122B2 (en) 2000-05-04
US5981247A (en) 1999-11-09
EP0859833B1 (de) 2006-03-01
JPH11514862A (ja) 1999-12-21
ATE318896T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Borman et al. elF4G and its proteolytic cleavage products: effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs.
Kessler et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase
Wirth et al. How a single Sindbis virus mRNA directs the synthesis of one soluble protein and two integral membrane glycoproteins
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
NO308310B1 (no) Hovedsakelig rent KGF protein og dets anvendelse
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
UA48936C2 (uk) Спосіб одержання вірусу курячої анемії (cav) у дволанцюговій формі, рекомбінантна нуклеїнова кислота (варіанти), діагностичний набір (варіанти), вакцинний препарат (варіанти), культура клітин (варіанти), спосіб одержання діагностичного набору (варіанти)
Barth et al. The oligomerization reaction of the Semliki Forest virus membrane protein subunits.
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
GB9722320D0 (en) Human cell cycle checkpoint proteins
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
GB9810999D0 (en) Materials and methods relating to the expression of genes
Hansen et al. Presence of the cap-binding protein in initiation factor preparations from poliovirus-infected HeLa cells
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Robert et al. Interactions with tRNALys induce important structural changes in human immunodeficiency virus reverse transcriptase
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
Skoging-Nyberg et al. MXI motif of Semliki Forest virus capsid protein affects nucleocapsid assembly
GR3007909T3 (de)
AP2368A (en) Novel expression vectors and uses thereof.
EP0282330A3 (de) Verfahren zur Stimulierung der Genexpression
Borovsky et al. Juvenile hormone affects the splicing of Culex quinquefasciatus early trypsin messenger RNA
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee